HCPCS code Q4184 – Cellesta amniotic membrane skin substitute

Key takeaways

HCPCS Code Q4184 covers Cellesta and Cellesta Duo, billed per square centimeter as an add-on code alongside the application procedure.

Units follow the square centimeters applied; Medicare pays only administered units, and the wound measurement supports medical necessity.

Q4184 is normally paired with a CPT application code from 15271-15278, chosen by wound site and total wound area.

From January 1, 2026, Medicare pays non-BLA skin substitutes such as Cellesta at a flat national rate of about $127 per square centimeter.

Pabau, practice management software with claims management built in, supports insurance billing for US practices.

HCPCS Code Q4184: What the code covers

HCPCS Code Q4184 covers Cellesta or Cellesta Duo, per square centimeter, and it is an add-on code.

You list it separately in addition to the primary skin substitute application procedure. The code applies to both the single-layer Cellesta product and the dual-layer Cellesta Duo, which share one descriptor. Both are human amniotic membrane allografts, classified as cellular and tissue-based products (CTPs) under CMS’s HCPCS Level II coding system.

Q4184 is a temporary Q code, which CMS issued outside the annual CPT cycle so the product could be billed before a permanent code existed. Codes in the Q4100-Q4397 range cover skin substitutes and CTP products, and our HCPCS code reference lists the rest of the range.

What Q4184 does not cover: Exclusions and limitations

Q4184 is product-specific. It does not cover other amniotic membrane or skin substitute products, even when they are clinically similar to Cellesta. Using Q4184 for a different manufacturer’s amniotic product is a coding error that will trigger a denial.

• Other amniotic products: EpiFix, Grafix, AmnioBand, and any other amniotic allograft not labeled Cellesta or Cellesta Duo carry their own Q codes. Even Cellesta Flowable Amnion has a separate code, Q4185.
• Non-covered wound types: Wounds are excluded, whatever the product, if they fall outside the governing Local Coverage Determination (LCD), where one exists. Without an LCD, your MAC’s reasonable-and-necessary review decides.
• Debridement at the same encounter: When Cellesta goes on at the same visit as aggressive debridement, payers may bundle or deny the Q code. Modifier use and sequencing decide which.
• Non-qualifying settings: The governing LCD, where one exists, or your MAC’s reasonable-and-necessary review can restrict coverage to specific care settings. Applying Q4184 in an excluded setting is a common denial trigger.
• Units the record does not support: Billed units must match the product applied and documented; Medicare does not pay discarded non-BLA units. The wound measurement then has to show the application was medically necessary.

How Q4184 units are calculated (per square centimeter)

Units for Q4184 equal the square centimeters of Cellesta or Cellesta Duo applied at the encounter. Record any discard in the note, but Medicare does not pay it for non-BLA products. The wound measurement does a separate job. It supports medical necessity and decides which CPT application code goes on the claim.

Calculation steps:

1. Measure the wound length and width in centimeters at the time of application, and multiply them for the area in cm².
2. Record the size of the Cellesta piece you opened and how much of it you applied.
3. Record any unused portion that was discarded, with the reason it could not be used.
4. Bill only the applied amount as Q4184 units. For Medicare, the discard stays in the note and is not billed.

From 2026, Medicare treats Cellesta as an incident-to supply rather than a Part B drug, so the JW and JZ modifiers do not apply. CMS does not pay for discarded amounts of incident-to supplies under any circumstances. Keep JW and JZ for BLA-licensed products and for any payer that still asks for them.

The wound area also sets the application code. The examples below assume a wound on the trunk, arms, or legs.

When you treat multiple wounds at one encounter, add the areas of all wounds in the same anatomic site group for the CPT application code. One group covers the trunk, arms, and legs. The other covers the face, scalp, neck, hands, feet, genitalia, and digits. Report one primary code (15271/15273 or 15275/15277) plus add-on codes for the combined area. Wounds in different site groups are not added together, and each group gets its own primary code. Q4184 units equal the total square centimeters of Cellesta applied for the wounds those CPT codes cover. Payers differ on whether Q4184 goes on one line or is split per site group, so follow your MAC or payer.

Documentation requirements for Q4184 billing

Medicare and most commercial payers require specific medical record elements before they will pay a Q4184 claim. Missing even one of these is enough to trigger a denial or a post-payment audit request.

• Wound measurement: Length, width, and depth recorded in centimeters on the date of service, supporting medical necessity and the application code.
• Product size, amount applied, and amount discarded: The figures behind the billed units; the discard is documented but is not billed to Medicare.
• Product lot number and expiration date: Confirms the specific Cellesta or Cellesta Duo product applied. Payers use this to verify product identity against the Q code.
• Wound photographs: Pre-application photographs are expected under legacy LCDs and most payer policies to establish wound stage, size, and baseline condition.
• Diagnosis and medical necessity statement: The treating clinician must document why conservative wound care has failed and why a skin substitute is medically necessary. Cite the wound type, duration, and prior treatments attempted.
• Physician order: A signed order authorizing Q4184 application, including the product name, quantity, and wound site.
• Application note: A procedure note describing the application method, any wound bed preparation performed, and post-application dressing.

A structured superbill that captures product identifiers alongside diagnosis and procedure codes reduces the risk of incomplete claims leaving your practice.

CPT codes billed alongside Q4184

Q4184 covers only the skin substitute product itself. The work of applying it is reported separately with a CPT application code from 15271-15278. Wound site and total wound area decide which one.

Confirm which CPT codes your MAC LCD authorizes alongside Q4184 before billing. Some MACs restrict the application CPT to specific wound types even when the Q code is covered. A consistent claims management workflow keeps the code pair and the note in step. The matrix below shows how site and total area pick the pair.

Neighboring Q codes: How HCPCS Code Q4184 differs

The Q4xxx series contains dozens of skin substitute codes, and the product names are similar enough that coders regularly transpose them. The table below covers the codes most often confused with Q4184.

Verifying the product name, manufacturer, and registration against the current CMS HCPCS code file before billing is the only reliable safeguard against product-code mismatches. Use the AAPC HCPCS code lookup as a secondary check when the CMS file is not immediately available.

If the box on the shelf says AlloWrap rather than Cellesta, the claim belongs under Q4150, with its own units and documentation.

Medicare coverage and prior authorization for Q4184

Medicare coverage for Q4184 depends on the Medicare Administrative Contractor (MAC), and no single national coverage policy applies uniformly. The new skin substitute LCDs for diabetic foot ulcers and venous leg ulcers were withdrawn on December 24, 2025, before they took effect. CGS, Novitas, and First Coast kept their legacy skin substitute LCDs unchanged. Palmetto, NGS, WPS, and Noridian have no active LCD, so claims are judged on whether the service is reasonable and necessary. Check which applies in your jurisdiction before assuming coverage.

Where a legacy LCD applies (CGS, Novitas, First Coast), covered indications commonly include chronic diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Each must follow failed standard care. Those LCDs typically require at least four weeks of standard wound care first. Where no LCD exists, medical necessity is judged case by case. Non-covered indications typically include acute traumatic wounds, surgical wounds healing by primary intention, and wounds that have not been given a trial of conservative treatment.

Prior authorization: Traditional Medicare has no universal prior authorization requirement for skin substitute Q codes, with one exception. From January 1, 2026, the CMS WISeR model requires prior authorization for skin and tissue substitutes in selected states. The model runs in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. The skin substitute component did not start on January 1, 2026, in Arizona and Washington, because neither state had an active LCD. It still applies in New Jersey, Ohio, Oklahoma, and Texas, so verify against current CMS WISeR guidance.

Commercial payers and many Medicare Advantage plans also require prior authorization, and their rules vary by plan and market. Contact the payer before the first application, and record the authorization number in the medical record and on the claim. A claim sent without a required authorization is denied, and that denial is hard to appeal. Keeping up with medical billing compliance requirements across payers matters for any practice that bills skin substitutes regularly.

Common denial reasons for HCPCS Code Q4184 claims

Wound care practices billing Cellesta see a predictable set of denial patterns, and catching them before submission costs less than appealing afterward. A structured denial management process that stops these claims before they leave the practice cuts rework.

• Missing prior authorization: Commercial plans, Medicare Advantage plans, and WISeR states can require PA for skin substitute Q codes. Claims submitted without an authorization number on file are denied outright.
• Wrong product-code pairing: Billing Q4184 for a product other than Cellesta or Cellesta Duo. Payers cross-reference the product lot number against the code descriptor.
• Units the note does not support: Billed units higher than the product applied. Payers compare claim line units against the clinical note.
• Incomplete documentation: Missing wound photographs, absent lot number, or no prior conservative treatment record. Each is a separate denial trigger under LCD documentation requirements.
• Non-covered place of service: Applying Cellesta in a setting your MAC’s policy or the payer does not accept. One example is an ASC where the MAC does not allow skin substitute application (see the place of service table below).
• Application frequency exceeded: Legacy LCDs and some payer policies cap how many applications per wound episode are covered. Exceeding the limit without a documented exception leads to denial of the extra encounters.
• Missing companion CPT code: Submitting Q4184 without a paired application CPT from the 15271-15278 series. The Q code covers the material, and the CPT code covers the work.

Reviewing each of these categories against a clean claim checklist before submission catches most Q4184 denials before they leave the billing queue. Make it a standard pre-submission step for all skin substitute encounters.

Q4184 reimbursement rates and place of service

From January 1, 2026, Medicare pays skin substitutes that are not licensed as biologics, Cellesta among them, as incident-to supplies under the Physician Fee Schedule. They are paid at a single national rate per square centimeter, about $127. After the November 2025 correction, CMS set it at $127.14. Always verify the current rate with the CMS Physician Fee Schedule search tool on the CMS site.

Reimbursement also varies by place of service. The three most common settings for Q4184 are:

These facility payment rules cover sheet-form skin substitutes such as Cellesta. Non-sheet products stay packaged under OPPS in 2026, so confirm the rules with your MAC before you bill.

A wrong POS code on a Q4184 claim is a denial in its own right, separate from any clinical documentation issue. Cross-check the POS against the performing location before submission. A medical billing process that checks the POS against the scheduled location stops that mismatch before it reaches the payer.

How claims management software supports accurate Q4184 billing

In many wound care practices, the Cellesta size, the wound measurement, and the authorization number live in three places. The chart holds one, a spreadsheet holds another, and the payer portal holds the third. Each hand-off is a chance for the units or the companion CPT code to drift away from the note.

Pabau, the practice management platform we build, keeps the patient record and the billing work in one system. Its claims management supports insurance billing in the US, so your billing team prepares the Q4184 claim from the same record the clinician documented in.

The outcome is less time chasing paperwork between the treatment room and the billing desk. Fewer claims come back for documentation the note already held.

Bill skin substitutes from one patient record

Pabau’s claims management supports insurance billing in the US, so wound care practices can prepare Q4184 claims from the record that holds the visit notes.

Book a demo

Conclusion

Every Q4184 claim rests on two decisions. The units come from the Cellesta you applied. The application code comes from the wound site and the total wound area. When the note answers both, the product mismatches and missing companion codes described above rarely reach the payer.

The rules shifted in 2026, with a flat national payment rate and WISeR prior authorization in selected states. Re-check your MAC’s guidance each quarter rather than trusting last year’s billing sheet.

Pabau’s claims management supports insurance billing in the US. Book a demo to see how your team can prepare skin substitute claims from the same record as the visit.

Continue your research

Need a broader overview of HCPCS billing workflows? Medical billing fundamentals covers how HCPCS and CPT codes interact in a complete revenue cycle.

Seeing recurring claim rejections across your wound care encounters? Denial management in healthcare outlines a systematic approach to tracking, appealing, and preventing repeat denials.

Want fewer errors before claims leave your practice? Pabau’s claims management software supports insurance billing in the US.

Billing skin substitutes to Medicare Part B? Medicare billing walks through the claim rules that sit behind every Q code.

Working with AlloWrap as well as Cellesta? HCPCS code Q4150 covers the neighboring amniotic product’s billing.

Frequently asked questions